I. Résumé analytique : La nécessité de modifier l'entraînement

La gestion de Fibrillation auriculaireAtrial fibrillation, often shortened to AFib, is a fast and irregular heartbeat that starts in the upper chambers of the heart. (FA) dans le athlète vétéranUn athlète masters est un concurrent de plus de 35 ans environ qui s'entraîne et court sérieusement, souvent pendant des décennies. (défini généralement comme l'âge de 35 ans et plus, et spécifiquement dans ce contexte comme 50 ans et plus) présente un défi critique qui nécessite une évolution nuancée de la philosophie d'entraînement. Bien que l'entraînement d'endurance chronique offre de nombreux bienfaits cardiovasculaires, il est fondamentalement dose-dépendant facteur de risqueUn facteur de risque est quelque chose qui augmente votre probabilité de développer une maladie : des particules de cholestérol élevées, une tension artérielle élevée, le tabagisme, le diabète, des antécédents familiaux. pour les arythmies auriculaires. Pour un athlète ayant subi un traitement (ablation ou thérapie pharmacologique) pour une FA, la poursuite d'un entraînement intense et à volume élevé comporte une probabilité substantielle de récidive de l'arythmie et de progression de la maladie.

La conclusion principale étayée par la recherche en électrophysiologie est que l'athlète vétéran (50 ans et plus) diagnostiqué et traité pour une FA devrait immédiatement et significativement modérer le volume et l'intensité de son entraînement d'endurance. Cette réduction est requise non seulement pour un soulagement symptomatique, mais en tant que stratégie thérapeutique visant à stabiliser le substrat auriculaire et à réduire la morbidité à long terme. L'objectif devrait être de maintenir une condition cardiovasculaire élevée grâce à une activité structurée, d'intensité modérée à vigoureuse, tout en atténuant activement la contrainte structurelle et électrique associée à la performance d'endurance de pointe.

Piliers clés de la prise en charge clinique :

1. Ajustement de la dose d'entraînement : Réduire le volume d'entraînement axé sur l'endurance chronique de haute intensité (généralement défini comme >10 heures par semaine pendant de nombreuses années) ¹).
2. Stabilité du rythme et risque de récidive : Mettre en œuvre des protocoles d'exercices thérapeutiques, tels que Entraînement par intervalles aérobieA structured exercise method alternating short bouts of high-intensity effort with active recovery periods — for example, four minutes at near-maximal exertion followed by three minutes easy — shown in clinical studies to reduce AF burden and improve VO₂ max more effectively than continuous steady-state training., qui ont démontré qu'elles réduisent activement la charge de fibrillation auriculaire.²
3. AVCUn accident vasculaire cérébral se produit lorsque le flux sanguin vers une partie du cerveau s'arrête, soit en raison d'un blocage, soit d'une hémorragie. Prévention AdhérenceL'observance thérapeutique consiste à prendre réellement ses médicaments de la manière prescrite, jour après jour. à Anticoagulation orale (ACO)Drug therapy that reduces the blood's ability to clot, used in atrial fibrillation to prevent stroke caused by clots forming in the atria; common agents include warfarin and the newer direct oral anticoagulants (DOACs). les recommandations fondées sur les scores de risque individuels (par exemple, CHA2DS2-VASc) sont essentielles et l'emportent souvent sur les objectifs athlétiques, car une ablation réussie ne garantit pas universellement une protection contre l'accident vasculaire cérébral.⁴

II. Physiopathologie et probabilité statistique de la récidive de la FA

A. Le mécanisme causal : entraînement d'endurance et remodelage auriculaire

Le risque de Fibrillation auriculaire (FA) en Sportifs vétéransLes athlètes d'endurance de compétition ou hautement entraînés, généralement définis comme des individus âgés de plus de 35 ans qui pratiquent depuis des années un entraînement à haute intensité ou à grand volume, constituent la population principale étudiée dans la recherche sur le paradoxe de l'athlète, car leur long historique d'exercice peut paradoxalement être associé à des scores coronariens calciques élevés. est inextricablement lié aux adaptations physiologiques induites par un entraînement soutenu et à haut volume, souvent résumé par le modèle de la courbe en J ou en U de la dose d'exercice et du risque cardiovasculaire.⁵

Substrat structural et électrique cardiaque

La surcharge volémique chronique inhérente aux sports d'endurance (tels que le cyclisme, la course à pied ou la natation) entraîne un remodelage cardiaque spécifique, conduisant au “ cœur d'athlète ”.⁷ Alors qu'une grande attention est accordée aux modifications ventriculaires, c'est le remodelage auriculaireStructural and electrical changes in the atria — including enlargement, wall thickening, fibrosis, and altered ion-channel expression — that develop in response to chronic pressure or volume overload; in endurance athletes, sustained high cardiac output drives this process and increases AF susceptibility. cela prédispose l'athlète à la FEV. Ce remodelage comprend :

• Dilatation biatrialeEnlargement of both the left and right atria, a structural change driven in endurance athletes by years of high cardiac output and sustained volume loading; it creates a stretched, electrically unstable tissue environment that predisposes to atrial fibrillation.: Hypertrophie des oreillettes gauche et droite.⁷
• Fibrose myocardique Le développement de cicatrices microscopiques (fibrose) dans les parois auriculaires.⁸

Cette fibrose est particulièrement dangereuse car elle crée un environnement tissulaire électriquement hétérogène, constituant un substrat très propice à la formation de circuits électriques de macro-réentrée. Ces circuits soutiennent l'activité électrique désorganisée caractéristique de la Fibrillation Atriale.⁸

Déséquilibres autonomes comme déclencheurs

In addition to structural changes, endurance athletes experience profound fluctuations in their autonomic nervous system. They typically exhibit exaggerated tonus vagalThe level of activity of the parasympathetic (vagus nerve) branch of the autonomic nervous system acting on the heart; high vagal tone slows the resting heart rate and is generally cardioprotective, but in extreme endurance athletes it has been proposed to contribute to atrial fibrillation risk. at rest, leading to sinus bradycardia. However, intense or competitive exercise induces a powerful sympathetic surge. This swing in autonomic activity significantly shortens the atrial refractory periodThe brief interval after each electrical activation during which atrial muscle cells cannot respond to a new stimulus; when this period is shortened — as occurs during sympathetic surges or with vagal tone — the atria become more vulnerable to rapid, disorganized firing and AF onset., acting as a potent ectopic trigger that can initiate Afib episodes.⁸ In the Masters athlete (50+), the combination of exercise-induced remodeling and age-related risk factors (such as hypertensionL'hypertension est le terme médical pour la pression artérielle élevée. ou obésitéL'obésité signifie avoir un excès de graisse corporelle suffisant pour nuire à la santé., even if well-controlled) compounds this electrophysiological vulnerability.¹

B. Statistical Data on Recurrence Probability Post-Treatment

The probability of remaining free from atrial arrhythmia after treatment is notably challenged by the continuation of the underlying etiological stimulus (intense training).

Recurrence Post-Catheter Ablation (PVI)

For athletes undergoing ablation par cathéterA procedure in which a cardiologist threads a thin flexible tube (catheter) into the heart and uses energy — typically radiofrequency heat or cryotherapy — to destroy small areas of tissue responsible for triggering abnormal electrical signals; the main interventional treatment for AF., specifically Pulmonary Vein IsolationThe most common catheter ablation technique for AF, in which the four pulmonary veins — the usual sources of the triggering electrical impulses — are electrically disconnected from the rest of the left atrium. (PVI), the recurrence rates are often problematic. Observational data suggest that endurance athletes tend to experience higher rates of atrial arrhythmia recurrence than sedentary non-athletes after the procedure.¹⁰ Crucially, this recurrence often manifests not as the original Afib, but as flutter atypiqueA form of atrial flutter whose reentrant circuit does not follow the classic right-atrial pathway but instead arises from fibrotic or scarred tissue elsewhere in the atria; in athletes post-ablation, it often signals disease progression beyond the originally isolated pulmonary vein triggers..¹⁰ This phenomenon suggests that the disease process has progressed, with the original pulmonary vein triggers successfully isolated, but the underlying fibrotic substrate driving new arrhythmias elsewhere in the atrial tissue (non-pulmonary vein dependent).¹⁰

One study comparing PVI outcomes reported that athletes experienced similar arrhythmia-free survival at 3 years compared to non-endurance controls (87% vs. 85%, p=0.88).⁹ However, another comparison showed recurrence rates (freedom from AF and antiarrhythmic therapy) were 34% in athletes versus 48% in controls after 3 years.⁹ The implication of this variation is that while PVI may be effective initially for vagally-mediated Afib common in athletes, the long-term maintenance of intense training will relentlessly drive further remodeling and increase the probability of eventual recurrence or progression to more complex arrhythmias like atrial flutter.¹⁰

Quantitative Benefit of Training Modification

A structured reduction and modification of exercise volume are strongly supported by outcome data, translating to a favorable reduction in recurrence probability.

• Risque relatifLe risque relatif compare deux groupes : ce groupe a enregistré 30 pour cent d'infarctus en moins que cet autre groupe. Reduction: Structured exercise intervention has been associated with an overall reduced risk of Récidive de FAThe return of atrial fibrillation after a period of successful rhythm control, whether achieved by ablation or medication; in endurance athletes, recurrence rates after a single ablation are approximately 40%, and persistent atrial enlargement and fibrosis are the main predictors. compared to control groups, quantified by a Relative Risk (RR) of 82 (95% CI: 0.68 to 0.99, p=0.04).³ This reduction suggests that thoughtful exercise prescription, focused on health maintenance rather than maximum performance, can be genuinely therapeutic.
• Reduction in Afib Burden: Specifically, structured Aerobic Interval Training (AIT) was found to reduce the mean time an athlete spent in Afib from 1% to 8.1% compared to a control group, alongside improvements in cardiopulmonary fitness (V02max).²

C. The Unacceptable Risk of Stroke

The decision to continue intense training must be weighed against the persistent risk of stroke, particularly because the athlete is over 50 years of age. Age 50+ likely results in a score CHA2DS2-VAScA clinical scoring tool used to estimate stroke risk in patients with atrial fibrillation, assigning points for risk factors such as age, sex, hypertension, diabetes, heart failure, prior stroke, and vascular disease; a score of 2 or higher typically triggers a recommendation for oral anticoagulation. of at least 1 (for age), possibly 2 or higher if other risk factors like hypertension or diabèteLe diabète est une affection où la glycémie reste trop élevée, soit parce que l'organisme produit trop peu d'insuline, soit parce qu'il cesse de répondre à l'insuline qu'il produit. are present.⁴

Stroke prevention guidelines dictate the use of Oral Anticoagulation (OAC) based on the CHA2DS2-VASc score, regardless of the perceived success of Afib treatment.

• OAC Discontinuation Risk: Observational studies indicate that for patients with a CHA2DS2-VASc score > 2, discontinuing OAC >3 months after catheter ablation led to a substantially increased stroke risk, quantified by a Rapport des risques instantanésUn rapport des risques instantanés compare la rapidité avec laquelle les événements se produisent dans deux groupes. Un rapport de 0,75 signifie que les événements se sont produits à un rythme égal aux trois quarts dans le groupe traité. (HR) of 2.48 (95% CI, 1.11–5.52; P<0.05).⁴
• Ablation Limitations: Randomized essais cliniquesUn essai clinique est une étude dans laquelle des chercheurs administrent un traitement à un groupe et un placebo ou des soins standard à un autre groupe, puis comparent les résultats. have, to date, not demonstrated reductions in stroke risk after catheter ablation.⁴

This data underscores the fact that ablation treats the arrhythmia symptom, but may not fully resolve the underlying pathology that drives thromboembolic risk. Therefore, the probability of stroke is overwhelmingly dependent on the CHA2DS2-VASc score, not on the ability to return to intense training. If OAC is required, the athlete must be counseled that contact or high-trauma sports are contraindicated due to bleeding risk.¹¹

III. Suggested Course of Action: Detailed Training and Clinical Protocols

The course of action for the Masters athlete (50+) with treated Afib should focus on risk mitigation and structured exercise for cardiac resilience.

A. Phased Training Modification Protocol

The transition from a high-volume endurance regimen to a therapeutic regimen requires structured phasing and communication, especially regarding the established link between high-intensity training and Afib burden.⁵

 

Phase	Durée	Activity/Goal	Clinical Rationale and Guidance
Phase 1: Immediate Post-Treatment Recovery	Initial 4–8 Weeks	Complete cessation or very light, non-competitive activity (e.g., walking).	Allows for myocardial healing and stabilization of sinus rhythm following ablation or cardioversion.12 Resumption of structured sports activity should begin only one month after ablation, provided the procedure is verified as successful.11
Phase 2: Therapeutic Load & Maintenance	Ongoing (Long-Term)	Moderate-to-Vigorous Structured Aerobic ExerciseL'exercice aérobique est une activité soutenue qui vous fait respirer plus fort pendant un certain temps, comme la marche rapide, le vélo, la natation ou le footing., prioritizing shorter, higher-intensity intervals (AIT) over long, continuous duration.	The primary long-term objective is to maintain aptitude cardiorespiratoireLa forme cardiorespiratoire correspond à la capacité de votre cœur, de vos poumons et de vos muscles à travailler ensemble pour utiliser l'oxygène lors d'un effort intense. Elle est souvent mesurée par le VO2 max. (improved V02max) and cardiac function (improved Left Ventricular Ejection FractionThe percentage of blood pumped out of the heart's main pumping chamber with each beat; a normal value is 55 percent or above, and a rising ejection fraction after heart disease is a measurable sign of cardiac recovery., LVEF 3), while avoiding the chronic volume strain that induced the Afib.13 The suggested target is approximately 210 minutes per week of moderate-to-vigorous aerobic exercise.4

The importance of using Entraînement par intervalles aérobie in Phase 2 cannot be overstated, as subgroup analysis suggests interval training offers greater benefit in reducing AF recurrence compared to continuous training.³ A generalized return to long, slow distance training (>10 hours/week) should be actively discouraged, as this risks re-inducing the remodeling that caused the original arrhythmia.¹

B. Clinical Management Considerations

1. Antiarrhythmic Medication and Performance: Athletes are often intolerant of or unwilling to take medications like Beta-blockers, as these drugs profoundly reduce peak capacité d'exerciceExercise capacity is a quantitative measure of the maximum physical work a person can perform, typically assessed during a graded stress test as peak workload in watts, peak oxygen consumption (VO2 max), or metabolic equivalents (METs). In the article, a decline in exercise capacity four months after stenting indicated that the procedure alone had not resolved the underlying disease., measured by V02max.¹⁴ Catheter ablation is frequently preferred because it offers the possibility of eradicating Afib and allowing a return to competition without daily performance-limiting drug therapy.¹⁴ If “pill-in-the-pocket” Class I drugs (flecainide or propafenone) are used for acute cardioversion, the athlete must refrain from intensive sports until two half-lives of the drug have elapsed (up to 2 days) due to the risk of pro-arrhythmic effects during adrenergic stress.¹¹
2. Monitoring and Evaluation: All athletes must be managed in a specialized sports cardiology center.¹ Exercise stress testing should be conducted using protocols that mimic the athlete’s sport to ensure the ventricular rate remains controlled during maximal exertion, confirming therapeutic efficacy.¹
3. Anticoagulation Status: OAC status must be re-evaluated continuously. In high-risk athletes (CHA2DS2-VASc >2), OAC must be continued indefinitely, even if Afib appears suppressed.⁴ This clinical requirement guides participation in sports; sports with high risk of bodily contact or trauma are strictly not recommended for anticoagulated individuals.¹¹

IV. Summary and Integration of Lipid Management (Stoicescu et al., 2025)

The holistic management of a Masters athlete (50+) requires addressing not only the electrophysiological disorder (Afib) but also the generalized cardiovascular risk, including lipid metabolism. The provided review paper, “HDLLe HDL, ou lipoprotéine de haute densité, est la particule souvent appelée " bon cholestérol ". Il récupère le cholestérol des tissus et le ramène vers le foie. Function Versus LDL petites et densesSmall dense LDL particles are LDL particles that are smaller and carrying less cholesterol than usual.: Cardiovascular Benefits and Implications” ¹⁵, provides essential context for managing atherosclerotic risk (ASCVD) in this population.

A. Paper Summary: HDL Function Versus Small Dense LDL

The review by Stoicescu, Vacarescu, and Cozma highlights a significant paradigm shift in lipidology: the focus has moved away from High-Density LipoprotéineUne lipoprotéine est un tout petit paquet qui transporte les graisses et le cholestérol dans votre circulation sanguine. Comme la graisse ne se dissout pas dans l'eau, elle a besoin d'une enveloppe protéique pour voyager. CholestérolLe cholestérol est une substance cireuse dont votre corps a besoin. Il entre dans la composition des parois cellulaires, des hormones, de la vitamine D et de la bile qui digère vos aliments. Vous en mettriez sans lui. (HDL-C) concentration toward functional capacity and aggressive reduction of particules athérogènesLes particules athérogènes sont les lipoprotéines contenant de l'ApoB — notamment les LDL, IDL, VLDL et la lipoprotéine(a) — qui peuvent pénétrer et être retenues dans la paroi artérielle pour initier et alimenter la croissance de la plaque ; l'article utilise ce terme pour décrire ce qui doit être abaissé de manière substantielle et durable pour obtenir la régression de la plaque..¹⁷

1. HDL Focus: Function over Quantity: While HDL traditionally was considered cardioprotective, pharmacologically increasing HDL-C concentration—via agents like NiacineLa niacine est la vitamine B3, qui, à très fortes doses, réduit le LDL et augmente le HDL. (AIM-HIGH, HPS2-THRIVE trialsA large randomized trial testing whether adding extended-release niacin plus laropiprant to background statin therapy reduced major vascular events in high-risk patients; it found no meaningful cardiovascular benefit and identified increased rates of serious adverse events, effectively ending niacin as a mainstream cardiovascular therapy.) ou CETP inhibitorsA class of drugs designed to block cholesterol ester transfer protein, an enzyme that shuttles cholesterol from HDL to LDL particles; clinical trials such as ILLUMINATE and ACCELERATE showed that pharmacologically raising HDL-C this way did not reduce cardiovascular events, shifting the field's focus toward HDL function rather than concentration. (ILLUMINATE, ACCELERATE trialsUn vaste essai randomisé sur l'évacetrapib, qui a considérablement augmenté le cholestérol HDL et abaissé le cholestérol LDL sans toutefois réduire les événements cardiovasculaires chez les patients à haut risque, renforce l'idée selon laquelle le C-HDL est un marqueur plutôt qu'un facteur protecteur causal.)—did not consistently reduce cardiovascular events.¹⁶ The predictive and protective value lies instead in HDL functionality, particularly its Capacité d'efflux du cholestérolCholesterol efflux capacity is a laboratory test of how well someone's HDL actually pulls cholesterol out of cells — a measure of function rather than quantity. (CEC), which represents its ability to remove cholesterol from macrophagesUn macrophage est une grande cellule immunitaire qui engloutit les débris et les envahisseurs. Le nom signifie littéralement "grand mangeur"." dans plaques artériellesA deposit within the artery wall made up of lipids, immune cells, cellular debris, and fibrous tissue that accumulates over time and can narrow or block blood flow; also called an atherosclerotic lesion or atheroma..¹⁶
2. sdLDL: The Principal Atherogenic Target: Small Dense Low-Density Lipoprotein (sdLDL) particles are identified as critically atherogenic.¹⁶ Their physical characteristics—small size, higher density, and low antioxydantAn antioxidant is a substance that mops up damaging molecules in the body. Vitamin E and beta-carotene are examples. content—allow them to penetrate the arterial intimaL'intima est la couche la plus interne de la paroi d'une artère, située juste sous laL'intima est la couche la plus interne de la paroi d'une artère, située juste en dessous de la doublure lisse. efficiently and undergo oxidative modification.¹⁵ Furthermore, their prolonged plasma half-life (up to 74 hours) increases their exposure time to the endothelial environment.¹⁵ Elevated sdLDL concentrations are strongly associated with increased ASCVD event risk (Adjusted HRs: 1.21 to 1.52).¹⁶
3. Therapeutic Consensus: Current guidelines prioritize reducing the overall burden of atherogenic lipoproteins, measured pragmatically by non-HDL-C or ApolipoprotéineUne apolipoprotéine est une protéine attachée à une particule transporteuse de graisses dans votre sang. Les graisses et l'eau ne se mélangeant pas, ces protéines agissent comme une enveloppe qui permet aux graisses de voyager en toute sécurité dans la circulation sanguine. BApoBL'ApoB est une protéine située à la surface de chaque particule de cholestérol susceptible de se coincer dans la paroi de vos artères et de provoquer de la plaque. Chacune de ces particules transporte exactement une ApoB.), which effectively targets sdLDL and remnant particles. StatinesUne statine ralentit l'enzyme que votre foie utilise pour fabriquer le cholesterol. Votre foie réagit en extrayant plus de cholesterol de votre sang, ce qui est la veritable source de bienfaits. et Inhibiteurs de PCSK9Un inhibiteur de la PCSK9 est un médicament qui bloque cette protéine destructrice de cholestérol, laissant plus de sites de liaison disponibles pour éliminer les particules du sang. remain the foundation of therapy, reducing LDL-C and ApoB.¹⁶

B. Third-Order Integration: Dual Risk Management Strategy

The physiological mechanisms driving Afib risk (remodeling/fibrosis) and those driving atherosclerotic risk (sdLDL accumulation/inflammationL'inflammation est la réponse de votre système immunitaire à une blessure ou à quelque chose qu'il traite comme un envahisseur. Elle entraîne gonflement, chaleur et cellules de nettoyage.) often overlap in the aging athlete. The approach must be comprehensive.

The necessity of managing Afib recurrence through exercise moderation paradoxically supports optimizing bilan lipidiqueUn bilan lipidique qui mesure le cholestérol total, le cholestérol LDL, le cholestérol HDL et les triglycérides, utilisé pour évaluer le risque cardiovasculaire et surveiller l'effet des interventions diététiques ou médicamenteuses. via lifestyle:

1. Lifestyle Synergy: Structured physical activity (moderate-to-vigorous exercise) and appropriate dietary modifications (e.g., Mediterranean, rich in graisses insaturéesLes graisses insaturées sont liquides à température ambiante et proviennent des plantes et des poissons — huile d'olive, noix, graines, avocat, huiles de graines. comme huile d'oliveL'huile d'olive est la principale matière grasse du régime méditerranéen, riche en graisses mono-insaturées et, dans sa forme extra vierge, en composés végétaux appelés polyphénols. ¹⁶, and low in refined glucidesLes glucides sont les sucres et les amidons présents dans les aliments : pain, riz, pâtes, fruits, pommes de terre, bonbons.) simultaneously address both cardiac risks. These changes improve overall cardiometabolic profile, enhance HDL functional capacity (increasing CEC and antioxidant potential), and reduce plasma triglyceride levels, thereby diminishing the hepatic production of sdLDL.¹⁶
2. Targeted Residual RiskLe risque résiduel est le risque qui subsiste après avoir fait ce qui est évident — cholestérol traité, tension artérielle contrôlée, non-tabagisme. Mitigation (Omega-3): Given the high ASCVD risk associated with sdLDL and remnant particles, pharmacological intervention may be warranted if hypertriglyceridemia (e.g., > 150 mg/dL) persists despite optimal statin therapy and lifestyle changes. High-dose pharmaceutical-grade Eicosapentaenoic Acid (EPA) demonstrated a 25% relative risk reduction in major cardiovascular events in the essai REDUCE-ITA large randomized trial of 8,179 high-risk, statin-treated patients assigned to icosapent ethyl 4 g/day or mineral oil placebo; it reported a 25% relative risk reduction in major cardiovascular events and a number needed to treat of 21 over a median of 4.9 years..¹⁶ This is a targeted therapy for the residual risk driven by sdLDL.
3. Critical Nuance in EPA Use: A vital consideration for a patient with established Afib is the recognized possibility of increased Afib incidence associated with high-dose acides gras oméga-3Omega-3s are fats found mainly in oily fish, walnuts, and flaxseed..¹⁶ The decision to use high-dose EPA requires careful consultation with the electrophysiologistA cardiologist subspecialist who focuses on the electrical system of the heart, diagnosing and treating arrhythmias; responsible for performing catheter ablation and managing AF in athletes. to balance the certain benefit of ASCVD risk reduction against the potential for exacerbating the underlying arrhythmia.

V. Conclusions and Recommendations

For the Masters athlete (age 50+) successfully treated for Atrial Fibrillation, the clinical data strongly indicate that continued intense training represents an elevated, medically unacceptable risk to long-term cardiac stability. The need to slow and restructure intense training is a mandatory component of therapy, not a subjective lifestyle choice.

The statistical probabilities overwhelmingly support intervention:

• The probability of Afib recurrence and progression (e.g., to atypical flutter) remains high if the athlete maintains chronic, high-volume endurance training, as this perpetuates the underlying fibrose auriculaireMicroscopic scarring of atrial muscle tissue, often resulting from chronic mechanical stretch or inflammation; fibrosis disrupts normal electrical conduction and is a well-established predictor of AF recurrence after ablation..⁸
• Implementing a structured, therapeutic exercise dose (approximately 210 minutes per week of moderate-to-vigorous activity, favoring intervals) actively reduces the probability of AF recurrence (RR 82).³
• The probability of a stroke event increases substantially (HR > 2.5) if a high-risk athlete (CHA2DS2-VASc >2) prematurely discontinues OAC, underscoring that rhythm stability does not negate thromboembolic risk.⁴

Recommended Course of Action

1. Mandatory Training Shift: The athlete must transition their training goal from maximal endurance performance to cardiovascular health maintenance. This involves reducing volume below chronic high-dose thresholds (i.e., less than 10 hours per week of high-intensity activity) and emphasizing structured interval training for sustained fitness and reduced Afib burden.
2. Stroke Prevention Adherence: OAC status must adhere strictly to guideline recommendations based on the CHA2DS2-VASc score. For most Masters athletes over 50 with treated Afib, continued OAC is required, necessitating the avoidance of contact or high-trauma sports.
3. Holistic Risk Management: Integrate the management of Afib with the control of atherosclerotic risk (ASCVD). Prioritize lifestyle factors (dietary fat composition, carbohydrate restriction) that enhance HDL function and reduce the highly atherogenic sdLDL particles.¹⁶ Any adjunctive therapy, such as high-dose EPA for hypertriglyceridemia, requires careful consideration due to the potential interaction with Afib burden.
4. Expert Monitoring: The athlete’s return to play and training intensity must be guided by a cardiology team specializing in sports electrophysiology, using serial monitoring and exercise stress testing to confirm rhythm and rate control during exertion.¹

Références

1. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace. 2009;11(1):11-17. doi:10.1093/europace/eun289
2. Malmo V, Nes BM, Amundsen BH, et al. Aerobic Interval Training Reduces the Burden of Atrial Fibrillation in the Short Term: A Randomized Trial. Circulation. 2016;133(5):466-473. doi:10.1161/CIRCULATIONAHA.115.018220
3. Fukata E, Hardani R, Mukti N, Pranawa F, Rusnanta F, Rizal A. Physical Exercise Intervention Improves Cardiac Function and Reduce Recurrences in Non-permanent Atrial Fibrillation: A Systematic Review and Meta-analysis. J Saudi Heart Assoc. 2025;37(4):1459. Published 2025 Oct 10. doi:10.37616/2212-5043.1459
4. Noseworthy PA, Yao X, Deshmukh AJ, et al. Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc. 2015;4(11):e002597. Published 2015 Nov 5. doi:10.1161/JAHA.115.002597
5. Guasch E, Mont L. Diagnosis, pathophysiology, and management of exercise-induced arrhythmias. Nat Rev Cardiol. 2017;14(2):88-101. doi:10.1038/nrcardio.2016.173
6. Pelliccia A, Maron BJ, Di Paolo FM, et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. J Am Coll Cardiol. 2005;46(4):690-696. doi:10.1016/j.jacc.2005.04.052
7. Benito B, Gay-Jordi G, Serrano-Mollar A, et al. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation. 2011;123(1):13-22. doi:10.1161/CIRCULATIONAHA.110.938282
8. Katritsis G, Calkins H. Catheter Ablation of Atrial Fibrillation – Techniques and Technology. Arrhythm Electrophysiol Rev. 2012;1(1):29-33. doi:10.15420/aer.2012.1.29
9. Calvo N, Mont L, Tamborero D, et al. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace. 2010;12(1):30-36. doi:10.1093/europace/eup320
10. Heidbüchel H, Panhuyzen-Goedkoop N, Corrado D, et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil. 2006;13(4):475-484. doi:10.1097/01.hjr.0000216543.54066.72
11. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96. doi:10.1093/eurheartj/ehaa605
12. Elliott AD, Mahajan R, Lau DH, Sanders P. Atrial Fibrillation in Endurance Athletes: From Mechanism to Management. Cardiol Clin. 2016;34(4):567-578. doi:10.1016/j.ccl.2016.06.006
13. Menezes AR, Lavie CJ, De Schutter A, et al. Lifestyle modification in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis. 2015;58(2):117-125. doi:10.1016/j.pcad.2015.07.001
14. Lobo HM, Naves ÍG, Marçal SB, Canzi CC, Rodrigues ABS, Menezes AS Jr. Atrial Fibrillation in Endurance Training Athletes: Scoping Review. Rev Cardiovasc Med. 2023;24(6):155. Published 2023 May 26. doi:10.31083/j.rcm2406155
15. Stoicescu C, Vacarescu C, Cozma D. HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications. J Clin Med. 2025;14(14):4945. Published 2025 Jul 12. doi:10.3390/jcm14144945
16. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792
17.  Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383-2393. doi:10.1056/NEJMoa1409065